BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 25231413)

  • 1. TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence.
    Ye J; Ma C; Hsueh EC; Dou J; Mo W; Liu S; Han B; Huang Y; Zhang Y; Varvares MA; Hoft DF; Peng G
    EMBO Mol Med; 2014 Oct; 6(10):1294-311. PubMed ID: 25231413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-derived γδ regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence.
    Ye J; Ma C; Hsueh EC; Eickhoff CS; Zhang Y; Varvares MA; Hoft DF; Peng G
    J Immunol; 2013 Mar; 190(5):2403-14. PubMed ID: 23355732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity.
    Gao A; Liu X; Lin W; Wang J; Wang S; Si F; Huang L; Zhao Y; Sun Y; Peng G
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33653799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human regulatory T cells induce T-lymphocyte senescence.
    Ye J; Huang X; Hsueh EC; Zhang Q; Ma C; Zhang Y; Varvares MA; Hoft DF; Peng G
    Blood; 2012 Sep; 120(10):2021-31. PubMed ID: 22723548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Senescent T cells within suppressive tumor microenvironments: emerging target for tumor immunotherapy.
    Liu X; Hoft DF; Peng G
    J Clin Invest; 2020 Mar; 130(3):1073-1083. PubMed ID: 32118585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model.
    Yang S; Archer GE; Flores CE; Mitchell DA; Sampson JH
    Cancer Immunol Immunother; 2013 Nov; 62(11):1649-62. PubMed ID: 23982483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TLR8-Mediated Metabolic Control of Human Treg Function: A Mechanistic Target for Cancer Immunotherapy.
    Li L; Liu X; Sanders KL; Edwards JL; Ye J; Si F; Gao A; Huang L; Hsueh EC; Ford DA; Hoft DF; Peng G
    Cell Metab; 2019 Jan; 29(1):103-123.e5. PubMed ID: 30344014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy.
    Liu X; Si F; Bagley D; Ma F; Zhang Y; Tao Y; Shaw E; Peng G
    J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exhaustion and senescence: two crucial dysfunctional states of T cells in the tumor microenvironment.
    Zhao Y; Shao Q; Peng G
    Cell Mol Immunol; 2020 Jan; 17(1):27-35. PubMed ID: 31853000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TLR8-mediated activation of human monocytes inhibits TL1A expression.
    Saruta M; Michelsen KS; Thomas LS; Yu QT; Landers CJ; Targan SR
    Eur J Immunol; 2009 Aug; 39(8):2195-202. PubMed ID: 19637197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.
    Kuramitsu S; Ohno M; Ohka F; Shiina S; Yamamichi A; Kato A; Tanahashi K; Motomura K; Kondo G; Kurimoto M; Senga T; Wakabayashi T; Natsume A
    Cancer Gene Ther; 2015 Oct; 22(10):487-95. PubMed ID: 26450624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma.
    Carpenter RO; Evbuomwan MO; Pittaluga S; Rose JJ; Raffeld M; Yang S; Gress RE; Hakim FT; Kochenderfer JN
    Clin Cancer Res; 2013 Apr; 19(8):2048-60. PubMed ID: 23344265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy.
    Giuffrida L; Sek K; Henderson MA; Lai J; Chen AXY; Meyran D; Todd KL; Petley EV; Mardiana S; Mølck C; Stewart GD; Solomon BJ; Parish IA; Neeson PJ; Harrison SJ; Kats LM; House IG; Darcy PK; Beavis PA
    Nat Commun; 2021 May; 12(1):3236. PubMed ID: 34050151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD155T/TIGIT Signaling Regulates CD8
    He W; Zhang H; Han F; Chen X; Lin R; Wang W; Qiu H; Zhuang Z; Liao Q; Zhang W; Cai Q; Cui Y; Jiang W; Wang H; Ke Z
    Cancer Res; 2017 Nov; 77(22):6375-6388. PubMed ID: 28883004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [γδ1 T cells derived from breast cancer tissue induce immunosenescence of naive CD4
    Ruan J; Zhang X; Yao S; Zhang Y; Huang Y; Qiu J; Ma C
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2021 Jul; 37(7):623-632. PubMed ID: 34140074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P2X7 Receptor Activity Limits Accumulation of T Cells within Tumors.
    Romagnani A; Rottoli E; Mazza EMC; Rezzonico-Jost T; De Ponte Conti B; Proietti M; Perotti M; Civanelli E; Perruzza L; Catapano AL; Baragetti A; Tenedini E; Tagliafico E; Falzoni S; Di Virgilio F; Norata GD; Bicciato S; Grassi F
    Cancer Res; 2020 Sep; 80(18):3906-3919. PubMed ID: 32699136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlling T cell senescence in the tumor microenvironment for tumor immunotherapy.
    Ye J; Peng G
    Oncoimmunology; 2015 Mar; 4(3):e994398. PubMed ID: 25949919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.
    Garg TK; Szmania SM; Khan JA; Hoering A; Malbrough PA; Moreno-Bost A; Greenway AD; Lingo JD; Li X; Yaccoby S; Suva LJ; Storrie B; Tricot G; Campana D; Shaughnessy JD; Nair BP; Bellamy WT; Epstein J; Barlogie B; van Rhee F
    Haematologica; 2012 Sep; 97(9):1348-56. PubMed ID: 22419581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
    Guedan S; Chen X; Madar A; Carpenito C; McGettigan SE; Frigault MJ; Lee J; Posey AD; Scholler J; Scholler N; Bonneau R; June CH
    Blood; 2014 Aug; 124(7):1070-80. PubMed ID: 24986688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway.
    Lv Y; Zhao Y; Wang X; Chen N; Mao F; Teng Y; Wang T; Peng L; Zhang J; Cheng P; Liu Y; Kong H; Chen W; Hao C; Han B; Ma Q; Zou Q; Chen J; Zhuang Y
    J Immunother Cancer; 2019 Feb; 7(1):54. PubMed ID: 30808413
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.